Meet the team
Dr. Klaus Damm
Dr. Klaus Damm is an experienced and accomplished life science professional with extensive expertise not only in international business development, product and technology licensing but also in discovery research in the biotech and pharmaceutical industry. Most recently, as Licensing Director for Oncology at Amgen, Dr. Damm was responsible for scientific scouting, the evaluation and assessment of licensing and M&A opportunities, as well as identifying, structuring, and negotiating collaboration agreements for platform technologies, preclinical and clinical product opportunities. His skills and expertise were instrumental in Amgen’s 2012 acquisition of Micromet’s bispecific antibody platform and development candidates, which included the Phase 2 program for blinatumomab, now FDA approved and marketed as Blincyto.
Prior to Amgen, Dr. Damm held a similar position in R&D Licensing for Oncology at Boehringer Ingelheim in Germany. This is also where he started his more than 20 year career in the pharmaceutical industry, initially as head of a research group focusing on novel targets and mechanisms in oncology drug discovery. He could built upon a successful academic research career which always had him at the forefront of cutting edge science and included positions at the Max-Planck Institute in Munich, the Salk Institute in La Jolla, as well as the European Molecular Biology Laboratory (EMBL) and the Cancer Research Center (DKFZ) in Heidelberg. His research results, which covered diverse fields such as avian retroviruses, nuclear hormone receptors, and human telomere biology, were published in leading scientific journals, including Nature and PNAS. He is also an inventor on a number of US and international patents. Dr. Damm is a molecular and cell biologist by training and holds a Ph.D. from the University of Heidelberg, Germany.